bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
Canada
All news
MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic
27 June, 2022The bioMérieux Canada team remained true to its commitment towards public health by ensuring the installation of the BIOFIRE® systems in record time. The team traveled across Canada despite the sanitary restrictions to ensure adequate user training and was able to demonstrate agility and innovation...
Scotland chooses VITEK® 2 for all NHS Microbiology Laboratories
19 March, 2007
National Procurement, a division of NHS National Services Scotland and the Scottish Microbiology Forum have awarded bioMérieux with a major contract to supply each of the 27 NHS (National Health Service) clinical microbiology laboratories in the country with a VITEK 2 system for standardising antibiotic susceptibility testing (AST) and bacterial identification.
bioMérieux Receives Major Order from BML, Japan’s Biggest Laboratory Chain
06 March, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces today that it has received a major order from BML, Inc. (BioMedical Laboratories), the biggest Japanese private laboratory chain. bioMérieux will supply 28 VITEK® 2 XL to BML.
bioMérieux confirms its commitment to the fight against Hospital Acquired Infections
15 February, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, confirms its commitment to the fight against Hospital Acquired Infections with the launch of three new products.
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program
04 January, 2007
Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
bioMérieux launches VIDAS® Troponin I Ultra
07 December, 2006
bioMérieux, a major player in the field of in vitro diagnostics, is reinforcing its commitment to combating cardiovascular diseases by launching VIDAS Troponin I Ultra, a first-line parameter in acute coronary syndrome diagnostics.
bioMérieux will be awarded up to €54.5 million by France’s Agence de l’Innovation Industrielle to pursue molecular biology research
24 November, 2006
bioMérieux today announced that it will be awarded up to €54.5 million over the next ten years by France’s Agence de l’Innovation Industrielle to help fund the “Advanced Diagnostics and New therapeutic Approaches” (ADNA) program, led by Mérieux Alliance. Of this amount, €25.6 million will be in the form of grants and €28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.
